08:00 AM EDT, 04/08/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that its drug Enhertu, which was jointly developed with Daiichi Sankyo, received approval from the US Food and Drug Administration for the treatment of unresectable or metastatic HER2-positive solid tumors.

The approved indication is for adult patients who have received prior systemic treatment and have no satisfactory alternative treatment options, AstraZeneca ( AZN ) said.

Enhertu, a HER2-directed antibody drug conjugate, now has five approved indications, the company said.

Price: 66.95, Change: -0.5, Percent Change: -0.74